162 related articles for article (PubMed ID: 22546231)
1. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.
Furugohri T; Fukuda T; Tsuji N; Kita A; Morishima Y; Shibano T
Eur J Pharmacol; 2012 Jul; 686(1-3):74-80. PubMed ID: 22546231
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Shirasaki Y; Morishima Y; Shibano T
Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
Furugohri T; Morishima Y
Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban.
Morishima Y; Kamisato C; Honda Y
Blood Coagul Fibrinolysis; 2021 Apr; 32(3):209-215. PubMed ID: 33560005
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Furugohri T; Sugiyama N; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1076-83. PubMed ID: 22012070
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
7. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Perzborn E; Heitmeier S; Buetehorn U; Laux V
J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
[TBL] [Abstract][Full Text] [Related]
8. A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation.
Kamisato C; Furugohri T; Morishima Y
Thromb Res; 2016 May; 141():77-83. PubMed ID: 26974491
[TBL] [Abstract][Full Text] [Related]
9. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
11. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.
Bloemen S; Hemker HC; Al Dieri R
Haematologica; 2013 Apr; 98(4):549-54. PubMed ID: 23100275
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
13. The direct thrombin inhibitor melagatran counteracts endotoxin-induced endothelial leukocyte adherence and microvascular leakage in the rat mesentery. Rationale for the treatment of inflammatory disorders beyond sepsis?
Leithäuser B; Fassbender M; Eickhoff M; Elg M; Eichner G; Matthias FR
Clin Hemorheol Microcirc; 2007; 36(4):277-89. PubMed ID: 17502698
[TBL] [Abstract][Full Text] [Related]
14. Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
Honda Y; Morishima Y
Thromb Res; 2015 May; 135(5):958-62. PubMed ID: 25791908
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
16. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
Elg M; Gustafsson D
Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
[TBL] [Abstract][Full Text] [Related]
17. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Furugohri T; Shiozaki Y; Muramatsu S; Honda Y; Matsumoto C; Isobe K; Sugiyama N
Eur J Pharmacol; 2005 May; 514(1):35-42. PubMed ID: 15878322
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
19. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Honda Y; Kamisato C; Morishima Y
Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
[TBL] [Abstract][Full Text] [Related]
20. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
